SchrodingerSDGR
SDGR
About: Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
Employees: 787
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
48% more call options, than puts
Call options by funds: $10.3M | Put options by funds: $6.93M
26% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 27
7% more capital invested
Capital invested by funds: $1.12B [Q3] → $1.19B (+$77.5M) [Q4]
2.69% more ownership
Funds ownership: 94.5% [Q3] → 97.19% (+2.69%) [Q4]
2% more funds holding
Funds holding: 205 [Q3] → 210 (+5) [Q4]
15% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 75
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$32
24%
upside
Avg. target
$39
50%
upside
High target
$45
75%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Keybanc Scott Schoenhaus 38% 1-year accuracy 15 / 39 met price target | 24%upside $32 | Overweight Maintained | 16 Apr 2025 |
Piper Sandler Joseph Catanzaro 46% 1-year accuracy 12 / 26 met price target | 75%upside $45 | Overweight Maintained | 27 Feb 2025 |
Financial journalist opinion
Based on 4 articles about SDGR published over the past 30 days
Neutral
Business Wire
1 day ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2025, the company granted (i) a non-statutory stock option to purchase 3,300 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 12,866 shares of the company's common stock to six newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of.
Neutral
Business Wire
5 days ago
Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) strongly supports the U.S. Food and Drug Administration's (FDA) plan to reduce, refine or potentially replace current animal testing requirements with new approaches designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation. The FDA's roadmap encourages a number of computational approaches to predict drug properties. Schrödinger's widely used computational platform enables highly accur.
Positive
Zacks Investment Research
5 days ago
Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last?
Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Positive
Seeking Alpha
1 week ago
Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)
Schrödinger's stock surged after the FDA's initiative to phase out animal testing, benefiting its computational drug discovery platform. The company has strong collaborations with big pharma and a promising internal pipeline, despite past financial struggles and intense competition. Schrödinger's predictive toxicology initiative aligns with regulatory trends, enhancing drug development efficiency and safety.
Neutral
Business Wire
1 month ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on March 15, 2025, the company granted (i) a non-statutory stock option to purchase 1,575 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 6,943 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of.
Neutral
Business Wire
1 month ago
Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025.
Neutral
Seeking Alpha
1 month ago
Schrödinger: Still Waiting On A Catalyst
Schrödinger's Q4 2024 results and 2025 guidance were solid, yet the company's share price remains low due to ongoing losses. Cash burn is likely to moderate going forward, as investments in the company's internal pipeline have now stabilized. Regardless, cash burn concerns are misplaced, as Schrödinger has demonstrated that it can manage its liquidity position through things like partnerships and licensing.
Neutral
Seeking Alpha
1 month ago
Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Affairs Ramy Farid - President & Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President, R&D & Therapeutics Conference Call Participants Kyle Yang - Jefferies CJ Yeh - Leerink Partners Brendan Smith - TD Cowen Michael Ryskin - Bank of America Vikram Purohit - Morgan Stanley Malcolm Hoffman - BMO Capital Markets Matt Hewitt - Craig-Hallum Capital Group Chris Shibutani - Goldman Sachs Operator Thank you for standing by. Welcome to Schrödinger's conference call to review Fourth Quarter and Full Year 2024 Financial Results.
Negative
Zacks Investment Research
1 month ago
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.32 per share a year ago.
Neutral
Business Wire
1 month ago
Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results.
Charts implemented using Lightweight Charts™